---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000004"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:51:28.945653+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis

## Summary
- Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.
- Activity scores improved similarly in both arms; chronicity scores stable.
- Data differentiates LUPKYNIS from first-generation CNIs on nephrotoxicity.
- Further data to be presented at Congress of Clinical Rheumatology May 4-7, 2023.
- Conference call/webcast at 8:30 am EDT on April 5, 2023.

## SEC filing metadata
- accession: 0001600620-23-000004
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/0001600620-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/auph-20230405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000004
- JSON: https://secwatch.observer/filing/0001600620-23-000004.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.